Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer
Crossref DOI link: https://doi.org/10.1007/s00280-014-2628-0
Published Online: 2014-11-15
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kontopodis, E.
Kentepozidis, N.
Christophyllakis, Ch.
Boukovinas, I.
Kalykaki, A.
Kalbakis, K.
Vamvakas, L.
Agelaki, S.
Kotsakis, A.
Vardakis, N.
Georgoulias, V.
Mavroudis, D.
Text and Data Mining valid from 2014-11-15